百濟神州(06160.HK):「百澤安」獲歐美積極註冊進展
百濟神州(06160.HK)公佈,歐盟委員會已批準公司旗下產品替雷利珠單抗「百澤安」(TEVIMBRA)作爲單藥,用於治療既往接受過含鉑化療的不可切除、局部晚期或轉移性食道鱗狀細胞癌(ESCC)成人患者。
另外,美國食品藥物管理局(FDA)亦已經受理替雷利珠單抗的一項上市許可申請,用於一線治療不可切除的局部晚期、復發或轉移性的ESCC患者。
目前百濟神州已啓動超過20項與替雷利珠單抗聯用的潛在註冊性研究。百濟神州實體瘤首席醫學官Mark Lanasa表示,未來將繼續全力確保開發出替雷利珠單抗的全部潛力,從而滿足世界各地的臨牀未盡之需。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.